Summary of clinical trials in advanced non-clear cell RCC #GU24. The studies are small & pathology mixed ‘the moons of Jupiter’. The focus on PD1 & VEGF was not driven by the biology. Large randomised trials such as SAMETA exploring MET in selected papillary seems like progress.

📢 Our latest clinical study ‘’Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT trial)’’ is now out! ClinicalTrialGov n. NCT06302569 #CancerResearch #oncology AIOM ANTURE - Associazione Nazionale Tumore del Rene Meet-URO The Renal Medullary Carcinoma Research Foundation Tumori Journal IKCC Kidney Cancer

💥Hot topics in #genitourinarycancers ➡️Multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy Current trends highlighted by the Congress here in the #Editorial 👇 journals.sagepub.com/doi/10.1177/03… Giuseppe Procopio pic.x.com/9JgLZdNbg3

Cabozantinib plus Durvalumab is active and safe in platinum chemotx pregressing mUC and Variant Histologies patients. Data presented at #AIOM2024 AIOM Patrizia Giannatempo Giuseppe Procopio Andrea Necchi @valentinaguadalupi Roberto Iacovelli Daniele Raggi Alessandro Rametta

🌟 A heartfelt thank you to all speakers and participants 🌟 An exceptional international exchange on the management of urothelial carcinoma. A unique opportunity for collaboration and growth. Istituto Tumori Atim Uro Uno Oncoinfo associazionepalinuro Giuseppe Procopio 📸 Highlights from the day

We are proud to share that Istituto Tumori will be presenting several groundbraking abstract at #ASCOGU2025 ! These presentations highlight the continued commitment to pushing the boundaries of science. Join us to learn more and engage with our team ! #RCC #bladdercancer

Our poster has been selected for tomorrow’s poster walks 🤩Come to see it and enjoy the walk! #GU25 #collectingductcarcinoma

Have a look at this insightful article. Full article here: sciencedirect.com/science/articl… #ClinicalResearch #Oncology #Genitourinary #RenalCellCarcinoma

ESMO drop just crashed the site. Clinicians, researchers, and oncologists everywhere hitting refresh like it’s Taylor Swift ticket day. Science waits for no server. #ESMO25 #Oncology #CancerResearch #ESMOAbstracts #ESMOcrash Alessandro Rametta Eleonora Gusmaroli Simone rota ESMO - Eur. Oncology AIOM

The #ASCO25 #OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 #ProstateCancer #BladderCancer #kidneyCancer ⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

Just back from #ASCO25, where I joined an ecancer roundtable on recent updates in renal cell carcinoma. Great to exchange views with highly experienced colleagues in the field. 🎥 Video here: player.vimeo.com/video/10898609… Guillermo de Velasco Michael Serzan, MD Javier Puente #GUcancer #RenalCancer

Current status of adiuvant #immunotherapy in #RCC: a Delphi study coordinated by Bernard Escudier. Full article here: doi.org/10.1016/j.ejca… #CancerResearch #oncology #genitourinary #RCC #Immunotherapy

Today is #WorldKidneyCancerDay! To mark the occasion, Istituto Tumori is hosting a special event for patients about genitourinary cancers: a space for support, information, and connection. #KidneyCancer #GUcancer #Oncology #PatientSupport

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. Brian Rini, MD OncoAlert

Today, serum KIM-1 is the biomarker to explore in all stages of RCC, via EU Focus pubmed.ncbi.nlm.nih.gov/40619332/

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1 disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.

IMvigor011 𝗰𝘁𝗗𝗡𝗔+ → 𝗢𝗦/𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝘄𝗶𝘁𝗵 𝗮𝘁𝗲𝘇𝗼 𝗰𝘁𝗗𝗡𝗔– → 𝘀𝗽𝗮𝗿𝗲𝗱 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗜𝗢 Primum non nocere: treating only those with molecular evidence of disease. This is Huge! Congrats to Tom Powles and everyone involved 👏

📢 Our case report on metastatic Leydig cell tumor treated with CDK4 inhibition is now published in JCO Precision Oncology! 👉 doi.org/10.1200/PO-25-… A collaborative effort with JCO Precision Oncology Patrizia Giannatempo nicola nicolai Andrea Necchi Sumanta K. Pal, MD, FASCO